Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06498960 · ClinicalTrials.gov registry record · NA
Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
A NA study of Normal Pressure Hydrocephalus, sponsored by CereVasc.
- Recruiting
- Registry status
- NA
- Development phase
- 230
- Enrollment target
- 20
- Study locations
NCT06498960: Recruiting NA study of Normal Pressure Hydrocephalus, sponsored by CereVasc.
NCT06498960 is a NA study of Normal Pressure Hydrocephalus that is actively recruiting participants, run by CereVasc. The registered enrollment target is 230 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06498960, a NA study of Normal Pressure Hydrocephalus, is actively recruiting participants, sponsored by CereVasc.
- RECRUITING
- Registry status
- NA
- Development phase
- 230 participants
- Enrollment target
- 20
- Study locations
Study Summary
Prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.
Primary Outcome
The Primary Effectiveness Endpoint of this study is change in gait impairment at 6-months, compared to baseline. Change in gait impairment is defined as reduction in time required to complete the Timed Up and Go (TUG) test (stand up, walk 3m, turnaround, walk 3m, sit down).
Conditions Studied
Interventions
- DEVICE CereVasc eShunt System
- DEVICE VP Shunt
Study Locations (20)
New York
- Albany Medical Center - Albany
- University at Buffalo Neurosurgery - Buffalo
- Northwell Health - Manhasset
- NYU Langone Health - New York
- Icahn School of Medicine at Mount Sinai - New York
- Lenox Hill Hospital - New York
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Florida
- Baptist Medical Center - Jacksonville - Jacksonville
- University of South Florida - Tampa
Illinois
- Northwestern University - Chicago
- Advocate Lutheran General Hospital - Park Ridge
California
- University of Southern California - Los Angeles
Connecticut
- Yale University - New Haven
Indiana
- Indiana University - Indianapolis
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2031-06 |
| Phase | NA |
What NCT06498960 shows while recruiting
NCT06498960 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Normal Pressure Hydrocephalus appearing as the primary indexed condition, and to 2 interventions - of which CereVasc eShunt System is the first listed.
NCT06498960 names 20 study sites across 11 states, led by New York, Massachusetts, Florida.
Frequently Asked Questions
What is clinical trial NCT06498960 about?
NCT06498960 is a clinical study titled "Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus". Prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.
What is the current status of trial NCT06498960?
This trial is currently recruiting. It is a NA study. The enrollment target is 230 participants. The study started on 2024-11-26. Estimated completion is 2031-06.
What conditions does trial NCT06498960 study?
This clinical trial studies the following conditions: Normal Pressure Hydrocephalus.
What interventions are being tested in trial NCT06498960?
The interventions under investigation include: CereVasc eShunt System (DEVICE), VP Shunt (DEVICE).
Who is sponsoring clinical trial NCT06498960?
This trial is sponsored by CereVasc, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06498960 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Normal Pressure Hydrocephalus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06498960's enrollment target sits among peer trials
230 465th of 2000 higher than 1,533 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI